Use of proteasome inhibitors to treat dry eye disorders

• US 20040180859A1
• Filed: 03/24/2004
• Published: 09/16/2004
• Est. Priority Date: 05/21/2001
• Status: Active Grant

• Current Assignee: Novartis Ag
• Original Assignee: Alcon Incorporated
• Inventors: Hellberg, Mark R., Klimko, Peter G.
• Granted Patent: US 7,112,588 B2
• Time in Patent Office: Days
• US Class Current: 514/64
• CPC Class Codes: A61K 31/4015 having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• CPC Class Codes: A61K 31/407 condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine

Abstract

Proteasome inhibitors are useful for treating dry eye disorders and other disorders requiring the wetting of the eye.

Claims

1. A method for the treatment of dry eye which comprises administering to a mammal a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a proteasome inhibitor of the formula:

2. The method of claim 1, wherein the composition is topically administered to a mammal'"'"'s eye.

3. The method of claim 1 wherein the pharmaceutically effective amount of the proteasome inhibitor is 0.0001-1% w/v.

4. The method of claim 1 wherein the dry eye and other disorders requiring the wetting of the eye is symptoms of dry eye associated with refractive surgery.